Access to EMR and KIS by Community Pharmacists

Motion S4M-13657: Richard Simpson, Mid Scotland and Fife, Scottish Labour
That the Parliament congratulates the NHS in England on its deployment of access to the summary care record to all community pharmacies; considers important that access will only be provided after patient consent; understands that the chief executive of Community Pharmacy Scotland (CPS), Harry McQuillan, said that “I note with great interest the news from south of the border with regards to community pharmacy access to summary care records. As a pharmacist who accessed this technology over ten years ago, I would urge the Scottish Government to look into similar access for the community pharmacy network in Scotland to enhance patient care” and that the director for the Royal Pharmaceutical Society (RPS) in Scotland, Alex MacKinnon, commented that “this is great news for patients and community pharmacists in England. The Royal Pharmaceutical Society in Scotland and Community Pharmacy Scotland have been advocating for this for the best part of 15 years. Access to an electronic shared record will undoubtedly be a key enabler for the development of community pharmacists’ clinical role”, and, in order to improve efficiency and safety of patients and reduce the load on GPs, calls on the Scottish Government to work with key stakeholder bodies, including the RPS and the CPS, to enable similar access for Scotland’s community pharmacists to both the emergency care record and the key information summary (KIS) of patients as a matter of urgency.

Novel Treatment for Breast Cancer

Motion S4M-13656: Richard Simpson, Mid Scotland and Fife, Scottish Labour
That the Parliament understands that the use of intrabeam radiotherapy has the potential to substantially reduce the burden of radiotherapy in the treatment of women with breast cancer; recognises that this novel treatment was first tried at the Middlesex Hospital in 1998 and is now being undertaken routinely in the US, Germany, Australia, France and other countries; welcomes the guidance issued by the National Institute for Health and Care Excellence in July 2014 recommending a single dose intrabeam radiotherapy at the time of surgery to replace 15 sessions of post-operative radiotherapy; appreciates that this decision was taken after a randomised controlled trial led by University College London, the TARGIT-A trial, which was published in 2010 and showed at five year follow up in 2014 that results were not inferior to the previous 15 session treatment, and invites the Scottish Government to support the implementation of this new therapy for the benefit of patients and in the expectation of substantial savings in resource to the NHS.